JPMorgan analyst Jessica Fye reinstated coverage of Cerevel Therapeutics with a Neutral rating and $25 price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CERE:
- Cerevel Therapeutics to Present at Upcoming Investor Conferences
- Cerevel Therapeutics reports Q3 EPS (61c), consensus (63c)
- Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
- Insider Trading: Cerevel (NASDAQ:CERE) Gains on Director’s Massive Buy
- Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023